EBMT 2016 | Change of landscape in CLL treatment
John Gribben
• 4 Apr 2016
At the 42nd Annual Meeting of the European Society for Blood and Marrow Transplantation, held in Valencia, Spain, John Gribben, MD, from Barts Cancer Institute, London, UK, discusses the role of ibrutinib, idelalisib, and rituximab in the treatment of patients with chronic lymphocytic leukemia (CLL). The RESONATE-2 clinical trial of ibrutinib changed the treatment algorithm with patients being offered targeted therapies as initial therapy. This raises a question: are we entering a new era where chemotherapy is something in the past for CLL?
